Summit Therapeutics

SMMT Large Cap

Healthcare · Biotechnology

Updated: Apr 5, 2026, 17:43 UTC

$19.38

+2.43% today

52W: $13.83 – $36.91

52W Low: $13.83 Position: 24% 52W High: $36.91

🔗 Compare Brokers

Key Metrics

P/E Ratio

—

Price-to-Earnings

Forward P/E

—

Forward Price/Earnings

P/S Ratio

—

Price-to-Sales

EV/EBITDA

—

Enterprise Value/EBITDA

Div. Yield

—

Annual dividend yield

Market Cap

$15B

Market Capitalization

Revenue Growth

—

YoY Revenue Growth

Profit Margin

—

Net profit margin

ROE

-206.1%

Return on Equity

Beta

—

Market sensitivity

Short Interest

24.18%

% of float sold short

Avg. Volume

2,744,873

Average daily volume

Valuation Analysis

Signal

N/A

vs. S&P 500 avg P/E (24.7x)

Analyst Consensus

Buy

13 analysts

Avg. Price Target

$29.09

+50.1% upside

Target Range

$11.73 – $40.06

About the Company

Summit Therapeutics Inc., a biopharmaceutical company, focuses on discovery, development, and commercialization of patient, physician, caregiver, and societal friendly medicinal therapies. Its lead development candidate is ivonescimab, a bispecific antibody for immunotherapy through blockade of PD-1 with the anti-angiogenesis for the treatment of non-small lung cancer (NSCLC) and colorectal cancer (CRC). The company has also combined ivonescimab with chemotherapy, which is in phase III clinical trial for the patients with epidermal growth factor receptor, mutated, and locally advanced or metastatic non-squamous NSCLC; first-line metastatic NSCLC; and first-line unresectable metastatic CRC. It markets its products in the United states, Canada, Europe, Japan, Latin America, Middle East, and

Sector: Healthcare Industry: Biotechnology Country: United States Employees: 265 Exchange: NGM